AI-powered diabetic retinopathy screening shows promising results

AEYEHealth a provider of artificial intelligence-based diagnostics for retinal imaging along with Topcon Healthcare, Inc., a provider of digital solutions for "Healthcare from the Eye” and robotic diagnostic devices, announced results demonstrating exceptional efficacy and 100% imageability with the combination of Topcon's NW500 non-mydriatic retinal camera and AEYE Diagnostic Screening. Together, this solution sets a new standard for accessible, on-the-spot patient care, according to the companies.

In a study, AEYE-DS AI technology, in conjunction with the Topcon NW500, demonstrated the following results: Exceptional clinical diagnostic efficacy with 92% sensitivity and 90% specificity; unprecedented imageability, with 100% of patients receiving diagnostic results, with >99% successfully imaged on the first attempt without dilation

AEYE-DS is already FDA-cleared for use with Topcon's TRC-NW400 and can be accessed through the Harmony digital health platform. AEYE Health is seeking additional clearance for its autonomous screening solution in combination with the Topcon NW500. AEYE-DS is the only approved autonomous AI solution that requires a single image per eye and, with the NW500, does not require dilation therefore significantly improving the time to screen patients to under one minute.

This clinical data highlights the efficacy and usability of the Topcon NW500 with AEYE-DS AI technology. The powerful synergy of this solution, including Harmony, makes it ideal for a wide range of clinical settings, enabling on-the-spot, efficient, and accurate diagnostic screening and streamlining referrals for timely treatment.

"This is a great day for blindness prevention, as our partnership with Topcon Healthcare continues to advance diabetic retinopathy screening using AI," said Zack Dvey-Aharon, Ph.D., CEO of AEYE Health, in a statement. "With Topcon's NW500, we were able to achieve 100% imageability and virtually 100% success rate on the first attempt without dilation. This means all patients can be screened on the spot, ensuring no one is left out of this critical diagnostic opportunity. This amazing advancement will significantly increase adoption of AI screening in the US and around the world."

"To successfully scale DR screening for all patients, robotic and high-quality imaging combined with a robust AI algorithm is essential," said Ali Tafreshi, CEO and president of Topcon Healthcare, Inc. "The NW500 with AEYE-DS will empower primary care providers to improve patient outcomes and enhance adherence to diabetic retinopathy screenings.”